Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$40.84+0.35 (+0.86%)
Close on Nov 18, 2026Market cap $117.38MP/E –Yield –
Spruce Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Spruce Biosciences's free cash flow for the twelve months ending Dec 31, 2024 was -$55.96M. For fiscal 2024 it was -$55.96M. The highest annual figure on record is -$12.62M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$55.96M | – |
| FY2023 | Dec 31, 2023 | -$33.28M | – |
| FY2022 | Dec 31, 2022 | -$41.69M | – |
| FY2021 | Dec 31, 2021 | -$35.97M | – |
| FY2020 | Dec 31, 2020 | -$27.59M | – |
| FY2019 | Dec 31, 2019 | -$12.62M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.74M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.74M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.58M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.66M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.81M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.91M | – |
See a number that looks wrong?